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Daniel Giannella-Neto4, Klaus H Kaestner2*† and Maria Lúcia Corrêa-Giannella1*†
Abstract
To explore the molecular pathways underlying thiazolidinediones effects on pancreatic islets in conditions
mimicking normo- and hyperglycemia, apoptosis rate and transcriptional response to Pioglitazone at both
physiological and supraphysiological glucose concentrations were evaluated. Adult rat islets were cultured at
physiological (5.6 mM) and supraphysiological (23 mM) glucose concentrations in presence of 10 μM Pioglitazone
or vehicle. RNA expression profiling was evaluated with the PancChip 13k cDNA microarray after 24-h, and
expression results for some selected genes were validated by qRT-PCR. The effects of Pioglitazone were
investigated regarding apoptosis rate after 24-, 48- and 72-h. At 5.6 mM glucose, 101 genes were modulated by
Pioglitazone, while 1,235 genes were affected at 23 mM glucose. Gene networks related to lipid metabolism were
identified as altered by Pioglitazone at both glucose concentrations. At 23 mM glucose, cell cycle and cell death
pathways were significantly regulated as well. At 5.6 mM glucose, Pioglitazone elicited a transient reduction in islets
apoptosis rate while at 23 mM, Bcl2 expression was reduced and apoptosis rate was increased by Pioglitazone. Our
data demonstrate that the effect of Pioglitazone on gene expression profile and apoptosis rate depends on the
glucose concentration. The modulation of genes related to cell death and the increased apoptosis rate observed at
supraphysiological glucose concentration raise concerns about Pioglitazone’s direct effects in conditions of
hyperglycemia and reinforce the necessity of additional studies designed to evaluate TZDs effects on the
preservation of β-cell function in situations where glucotoxicity might be more relevant than lipotoxicity.
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Introduction
Type 2 diabetes is characterized by impaired insulin se-
cretion and reduced peripheral insulin sensitivity. Loss
of β-cell function causes not only the progression from
the prediabetic state to overt disease, but also hastens
the deterioration of metabolic control in people with
type 2 diabetes [1,2]. Thiazolidinediones (TZDs), a
family of peroxisome proliferator-activated receptor γ
(PPARγ) ligands, act by improving peripheral insulin
sensitivity [3]. Clinical studies have shown that treat-
ment with TZDs maintains β-cell function and prevents
high risk patients from progressing to diabetes [4-6].
Studies in rodents demonstrated that these drugs re-
duce β-cell impairment and decrease islet fatty acid ac-
cumulation [7,8]. It is known that activation of PPARγ
in vivo induces several peripheral adaptations that
result in improved insulin sensitivity and reduced insu-
lin demand, however, if there are direct effects such as
reduced lipotoxicity [9,10], protection from oxidative
stress and from apoptosis [11] remains to be further
investigated.
Apoptosis constitutes the main form of β-cell death
[12] and gluco- and/or lipotoxicity are two of the major
mechanisms for islets dysfunction and apoptosis in pan-
creatic cells in type 2 diabetes [13]. While TZDs have
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been reported to have direct beneficial effects on β-cells
by preventing these toxicities [14,15], by promoting
antioxidative effects [16] and by preventing β-cell dys-
function under conditions of concomitant hyperglycemic
and cytokine stress [17], this notion has been contested
by others [18,19]. To further explore the molecular
pathways underlying TZDs direct effects on pancreatic
islets in conditions mimicking normo- and hypergly-
cemia, we have determined transcriptional response and
apoptosis rate of rat islets to Pioglitazone, currently the
only TZD in clinical use, at both physiological and
supraphysiological glucose concentrations.
Methods
Islets isolation and culture
Islets were isolated from male Wistar rats (2 months of
age, 220-260 g) after perfusion of the pancreatic duct,
collagenase (Type V) digestion and purification on Ficoll
gradients [20] and cultured in RPMI-1640 media with
10% FCS, 5.6 mM glucose, 100 IU/ml penicillin and 100
μg/ml streptomycin. All reagents were obtained from
Sigma-Aldrich Chemical (St. Louis, MO, USA). All
animal procedures were in accordance with NIH’s
‘Principles of laboratory animal care’, and approved by
the local ethics committee.
Expression profiling
After 24 h of isolation, approximately 250 islets were
cultured with 10 μM Pioglitazone (Takeda Pharmaceuticals,
Japan) or DMSO (vehicle) for 24 h in either physiological
(5.6 mM) or supraphysiological (23 mM) glucose con-
centrations. Both control and treated culture media
contained 0.1% DMSO as a final concentration.
Two array experiments were performed in parallel
to analyze the effect of Pioglitazone at both glucose
concentrations (Figure 1). A direct comparison design
was used, such that hybridizations were set up as Test
(Cy5) vs. Control (Cy3). Five biological replicates were
used for each condition.
All RNA samples were analyzed using an Agilent
Bioanalyzer Lab-on-a-Chip Nano 6000 chip to deter-
mine the integrity and concentration of the samples.
Only samples with a RIN factor > 6.0 were used. Five μg
of total RNA was indirectly labeled using amino-allyl
dUTP and an anchored oligo (dT)20 to prime reverse
transcription. Methods for fluorescent labeling and data
acquiring were as described [21]. The high level of se-
quence similarity between mouse and rat genes makes
the Mouse PancChip array suitable for use with rat tis-
sue [22]. Statistical analysis was performed in “R” using
both the LIMMA [23] and Statistical Analysis of
Microarrays (SAM) package (http://www-stat.stanford.
edu/~tibs/SAM/) [24]. A one-class unpaired analysis
with a False-discovery rate (FDR) of 20% was employed.
The list of significantly differentially expressed genes was
filtered to remove genes with an absolute change ≤ 1.2
fold. Microarray data are available through the Minimum
Information About a Microarray Experiment (MIAME,
accession number GSE40119) [25]. Biologically relevant
Pioglitazone
5.6 mM Glucose
Vehicle
5.6 mM Glucose
Pioglitazone
23 mM Glucose
Vehicle
23 mMGlucose
Hybridization A
Physiological
Hybridization B
Supraphysiological
Figure 1 Microarray hybridization setup. Two experiments were
performed in parallel, at 5.6 mM (physiological) and 23 mM
(supraphysiological) glucose concentrations.
Table 1 Confirmation (by qRT-PCR) of gene expression
changes induced by 24-hour exposure to Pioglitazone at
5.6 mM and 23 mM glucose concentrations
Genes PanChip qRT-PCR
FC FDR FC p-value
5.6 mM Fabp4 1.6 14.57 5.8 0.02
Insig1 1.4 14.57 2.0 0.02
Scd1 1.5 14.57 1.2 0.32
Scd2 1.4 14.57 1.9 0.03
Sc4mol 1.3 17.95 1.2 0.44
23 mM Actb 1.4 6.5 1.6 0.17
Bad 1.4 5.0 1.4 0.05
Bax 1.3 4.0 1.5 0.02
Camk2b 1.3 9.3 1.2 0.42
Fabp4 1.4 4.0 5.0 0.02
Hmox1 1.4 7.3 3.4 0.04
ltpr2 1.3 4.0 1.5 0.04
Npy −1.3 2.3 −2.7 0.19
Prdx6 1.4 11.4 1.3 0.34
Sod2 1.4 6.7 4.5 0.02
Positive and negative FC (fold-change) represent, respectively, genes
upregulated and downregulated by Pioglitazone. FDR: false-discovery rate.
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networks were drawn from the two lists of differentially
expressed genes identified by SAM analysis. Ingenuity
Pathways Analysis (www.Ingenuity.com) was employed to
analyze networks affected by Pioglitazone as described [21].
Quantitative real-time reverse transcription PCR (qRT-PCR)
Differential gene expression was confirmed using qRT-
PCR, as previously described [21] on RNA prior to
amplification and using specific primers designed for rat
genes (Additional file 1: Table S1). Gapdh, Actb, Hprt
and Tbp were tested for their potential use as house-
keeping genes using the geNorm analysis package [26],
and Gapdh was selected as the most stable. Relative
levels of mRNA expression were calculated using the
2ΔΔCT method [27]. Five independent experiments were
performed in duplicate.
Evaluation of apoptosis
To evaluate the chronic effect of Pioglitazone on apoptosis,
islets were cultured in RPMI-1640 with 10% FCS and
exposed or not (vehicle) for 24, 48 and 72 h to 10 μM
Pioglitazone at 5.6 mM or 23 mM glucose. qRT-PCR was
performed as described above to analyze the expression of
the antiapoptotic gene Bcl2. The rate of apoptosis was
evaluated by quantification of DNA fragmentation with the
Cell Death Detection Enzyme-Linked Immunosorbent
Assay Plus Kit (Roche Molecular Biochemistry, Germany).
Aliquots of cytoplasmic lysates (50 islets/reaction) were
analyzed and quantified using an Anthos' LUCY-3
luminometer (Anthos Labtec Instruments, Australia) at
405 nm. Comparison of the absorbance of treated with un-
treated samples determined the extent of DNA fragmenta-
tion. Absorbance values from the samples were corrected
for the background values and the results were expressed
as arbitrary units (AU). To confirm the increased rate of
apoptosis in islets exposed to Pioglitazone and 23 mM glu-
cose at 48 and 72 h, caspase-3 enzyme activity was
measured using the ApoTarget Caspase-3 Protease Assay
Kit (BioSource International Inc, USA). Aliquots of cyto-
plasmic lysates (1,000 islets/reaction) were analyzed and
quantified using an Anthos' LUCY- luminometer at 405
Figure 2 Pathway analysis identifies a network of genes related to lipid metabolism in islets cultured at 5.6 mM glucose
concentration. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationships between the nodes).
Nodes are displayed using various shapes that represent the functional class of the gene product. The node color indicates up (red)- or down
(green)-regulation by Pioglitazone. Edges are displayed with various labels that describe the nature of the relationship between the nodes
(A, activation; B, binding; E, expression; I, inhibition; P, phosphorylation; T, transcription). Edges without a label represent binding only. The node
Srebf1 was identified by the pathway analysis as part of the network, and its differential gene expression was determined subsequently by qRT-
PCR. A total of 15 differentially expressed focus genes were brought into this network with a highly significant score of 30.
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nm. Results were corrected for protein content and
expressed as AU. Three independent experiments were
performed in triplicate.
To rule out a toxic effect of Pioglitazone, batches of 10
islets were cultured in RPMI-1640 with 10% FCS and
exposed or not (vehicle) for 24 h to 10 μM Pioglitazone
at 5.6 mM glucose and at 23 mM. The insulin secretory
response was studied after islet incubation for 1 h in
Kreb’ s buffer with 1.6 mM glucose for stabilization,
followed by incubation for 1 h at 1.6 or 16.7 mM glucose.
Incubation media were collected for insulin measurement
by ELISA (Linco Research, St Louis, USA). Results were
corrected for DNA content and stimulation indices were
calculated by dividing insulin secretion at high glucose by
basal insulin secretion. Three independent experiments
were performed in duplicate.
Statistical analysis
Statistical tests were performed using the JMP Version
6.0 statistical computer program (SAS Institute). The
Student’s t test was used to confirm that the qRT-PCR
results were significant and matched the direction of the
fold change predicted by the array. Because assumptions
for a parametric test were not valid (P < 0.05, Kolmogorov-
Smirnov), all data concerning apoptosis rate and measure-
ment of insulin content were evaluated by Wilcoxon-
Mann-Whitney after quantile transformation (Q), i.e.,
quantile data transformation is used for the construction
of the quantile-quantile (Q-Q) where the values in the
sample of data, in order from smallest to largest, are
denoted x(1), x(2), . . ., x(n). For i = 1, 2, ....., n, x(i) is plot-
ted against F-1((i-0.5)/n). Data were expressed as median
and semi-interquartile range. Statistical significance was
fixed at probability levels of < 0.05.
Results
The transcriptional response of the islet to TZDs
The transcriptional response of pancreatic islets to
Pioglitazone was determined at normal (5.6 mM) and
high (23 mM) glucose concentrations using the Panc-
Chip microarray. Expression of 101 genes was
modulated by Pioglitazone at 5.6 mM of glucose, with
Figure 3 Network related to lipid metabolism in islets cultured at 23 mM glucose concentration. For the explanation of the symbols and
letters, see the legend to Figure 2. A total of 19 differentially expressed focus genes were brought into this network with a highly significantly
score of 22. The node Srebf1 was identified by the pathway analysis as part of the network, and its differential gene expression was determined
subsequently by qRT-PCR. The node Ywhaz was tested for being included in the pathway, but it was not Pioglitazone dependent.
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49 upregulated by the drug and 52 downregulated. At
23 mM glucose 1,235 genes were affected, with 612
uregulated by the drug and 623 downregulated. The list
of all genes modulated by Pioglitazone at 5.6 mM and
the list of the 200 first genes down- and up-regulated by
Pioglitazone at 23 mM are shown on Additional file 2:
Tables S2 (5.6 mM) and Additional file 3: Table S3
(23 mM).
The microarray results were validated using qRT-PCR,
which closely mirrored the results of the array analysis
(Table 1). We also evaluated five genes previously
suggested as PPARγ targets, Gck, Slc2a2, Abca1, Lpl and
Ucp2, as well as the expression of Pparg, Ppara, Ins1
and Ins2. None of these genes were Pioglitazone
responsive in islets as determined by qRT-PCR (data not
shown).
Pathway analysis indicated a single gene network,
related to lipid metabolism, as Pioglitazone dependent at
5.6 mM glucose (Figure 2). Among the differentially
Figure 4 Network related to cell cycle and cell death in islets cultured at 23 mM glucose concentration. For the explanation of the
symbols and letters, see the legend to Figure 2. A total of 33 differentially expressed focus genes were brought into this network with a highly
significant score of 60. The three nodes Tnf, Myc and Lipe were identified by the pathway analysis as part of the network, and their differential
gene expression was determined subsequently by qRT-PCR.
Table 2 Analysis (by qRT-PCR) of the expression of
additional genes identified as Pioglitazone targets by
network analysis after 24-hour exposure to the drug at
5.6 mM and 23 mM glucose concentrations
Genes FC p-value
5,6 mM Srebf1 1.3 0.02
23 mM Aldob −1.8 0.05
Lipe 2.0 0.03
Myc 2.0 0.04
Scd2 1.5 0.01
Srebf1 1.3 0.03
Tnf 3.6 0.05
Positive and negative FC (fold-change) represent, respectively, genes
upregulated and downregulated by Pioglitazone.
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expressed genes included in this network six were
confirmed through qRT-PCR. All genes showed the
same degree and direction of change, but for Scd1 and
Sc4mol qRT-PCR data were not statistically significant
(Table 1). At 23 mM glucose the drug effect was much
more pronounced, and consequently the number of
regulated genes was dramatically increased. The two
most strikingly affected networks included genes related
to lipid metabolism, and cell death and cell cycle
(Figures 3 and 4, respectively). Among the 10 genes
selected for validation by qRT-PCR, six genes were
confirmed as differentially expressed after Pioglitazone
treatment (Table 1). Based upon the networks generated
by our pathway analysis, we tested additional key genes
by qRT-PCR. As shown in Table 2, all these genes were
also Pioglitazone dependent.
Evaluation of apoptosis
The measurement of insulin secretion performed to rule
out a toxic effect of Pioglitazone demonstrated that
glucose-stimulated insulin secretion was not significantly
different between islets exposed and not exposed to
Pioglitazone for 24 h, with stimulation indices of 2.0 ±
0.3 and 1.9 ± 0.4, respectively, in islets maintained at 5.6
mM glucose and of 3.2 ± 1.2 and 2.1 ± 0.9, respectively,
in islets maintained at 23 mM glucose.
In islets cultured at 5.6 mM glucose, Bcl2 RNA expres-
sion was not significantly modulated by Pioglitazone at
any of the evaluated time-points (Table 3). The apoptosis
rate was transiently decreased in comparison to untreated
islets after 48 h exposure to the drug (Figure 5). At 23
mM glucose, Bcl2 RNA expression was significantly lower
in islets treated with Pioglitazone for 24 and 48 h (Table 3).
In agreement with the reduction of expression of this
antiapoptotic gene, the apoptosis rate evaluated by
DNA fragmentation (Figure 6A) and caspase-3 activity
(Figure 6B) was shown to be increased by Pioglitazone
after 48 and 72 h.
Discussion
This study, designed to further investigate the direct
effects of Pioglitazone on pancreatic islets, demonstrates
that the effect of this TZD on islet apoptosis rate and gene
expression profile depends on the glucose concentration.
Parton et al. [28] had investigated gene expression
profiles of rat islets treated with a PPAR-γ agonist (GW-
347845) only at 3 mM glucose and found that 49 out
of 9,563 genes exhibited altered expression levels. A
substantial increase in the number of genes affected was
p< 0.05
Control
10 µM 
24 h 48 h 72 h
Figure 5 Apoptosis rate as measured by DNA fragmentation of islets exposed to Pioglitazone at physiological glucose concentration.
Box diagram comparing islet treated by Pioglitazone (10 μM) with non-treated cells (Control). The horizontal line within the box plot represents the
median value, the box plot limits refer to 25th to 75th percentiles, and the box plot bars include the 10th to 90th percentiles for apoptosis rate.
Table 3 Analysis (by qRT-PCR) of the Bcl2 expression
induced by 24-, 48- and 72- hour exposure to
Pioglitazone at 5.6 mM and 23 mM glucose
concentrations
Glucose concentration Time(h) FC p-value
5.6 mM 24 −1.2 ns
48 −1.1 ns
72 1.0 ns
23 mM 24 −3.0 0.001
48 −2.5 0.002
72 −1.1 ns
Negative FC (fold-change) represents downregulation by Pioglitazone.
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observed only when islets overexpressing PPAR-γ were
treated with GW-347845. Our current finding, in which
101 out of 13,059 genes were affected by Pioglitazone in
islets maintained at 5.6 mM glucose, suggests that gene
expression in β-cells is not very sensitive to TZDs in
euglycemic conditions and in cells with physiological ex-
pression of PPAR-γ. A further similarity between both
studies was the lack of modulation of the genes coding
for glucokinase and UCP2, previously suggested as
PPAR-γ targets [29,30].
At both glucose concentrations Pioglitazone increased
the expression of Scd2 and Fabp4, lipogenic genes which
are PPAR-γ targets in adipocytes [31,32] and Srebf1, a
transcription factor involved in lipogenesis in adipocytes
[33]. In the opposite metabolic direction, Pioglitazone
increased the expression of Insig1 (at 5.6 mM), a protein
that participates in the inhibition of cholesterol synthesis
[34] and of Lipe (at 23 mM), which codes for hormone-
sensitive lipase, responsible for hydrolysis of triglycerides
[35]. Thus, in conditions of physiological expression of
PPAR-γ, Pioglitazone stimulates expression of genes that
limit lipid accumulation in islets, but we cannot rule out
that these changes are a response to a primary activation
of lipogenic pathways, which is more concordant with
the role of PPAR-γ in other tissues.
The transcriptional response to Pioglitazone was stri-
kingly different under conditions of elevated glucose, an
effect not previously described. Concomitant treatment
Figure 6 Apoptosis rate as measured by DNA fragmentation (Panel A) and by caspase 3 activity (Panel B) of islets exposed to
Pioglitazone at supraphysiological glucose concentration. Box diagram comparing islet treated by Pioglitazone (10 μM) with non-treated
cells (Control). The horizontal line within the box plot represents the median value, the box plot limits refer to 25th to 75th percentiles, and the
box plot bars include the 10th to 90th percentiles for apoptosis rate.
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of islets with Pioglitazone and 23 mM glucose increased
by 12-fold the number of modulated genes. Little is
known about the mechanisms involved in glucose regu-
lation of β-cell gene expression. It has been suggested
that glucose metabolism alters gene expression directly
at the transcriptional level by interfering with proteins
bound to the preinitiation complex or by modifying the
concentrations of transcription factors [36]. Although
further studies are necessary to determine the contribu-
tion of enhanced RNA stability or direct transcriptional
activation on the observed response, it can be hypo-
thesized that at high concentrations, glucose interferes
with ligand-dependent PPAR-γ transcriptional activity,
directly modulating the expression of genes that are not
affected when islets are exposed solely to the PPAR-γ
ligand. However, since the transcriptional response to
Pioglitazone was determined after 24 h in the absence of
protein synthesis inhibitors, it is likely that part of the
observed gene regulation is not directly due to ligand
binding to PPAR-γ, but resulted from changes in expres-
sion of other transcriptional regulators targeted by the
combination of glucose and ligand. It is also worth
mention that both high glucose concentrations [37] and
PPAR ligands [38] promote chromatin remodeling
and transcription, which could also contribute to the
observed finding.
At 48 h, Pioglitazone elicited a reduction in islets
apoptosis rate at 5.6 mM glucose. The transient nature
of this response makes it difficult to state that this TZD
exerts a protective effect on pancreatic islets, but one
can conclude that in such experimental condition,
Pioglitazone is not deleterious, a result in contrast to
that obtained at supraphysiological glucose concentra-
tion, at which an increased apoptosis rate was found
after 48 and 72 h. This pro-apoptotic tendency was also
revealed by the gene expression analysis after 24 h, since
genes related to cell cycle and cell death were signifi-
cantly modulated. Because genes related to lipid meta-
bolism were also modulated at 5.6 mM, this single
pathway does not seem to be related to the apoptotic
fate of islets. Additional data that reinforce a pro-
apoptotic trend of islets exposed to Pioglitazone at 23
mM glucose are upregulation of antioxidant defense
genes such as Hmox1 and Sod2, believed to be activated,
respectively, in response to cellular stress [39] and in
ß-cell defense [40], and a lower Bcl2 RNA expression
after 48 and 72 h of exposure. Although several studies
have already demonstrated that TZD´s may counteract
direct fatty acid induced deleterious effects on β-cell
function [11,41-44], few studies addressed the direct
effects of TZD´s in conditions mimicking hyperglycemia.
Zeender et al. had found that Pioglitazone decreased the
apoptosis rate of human islets exposed to 33.3 mM glu-
cose after 48 h (5 μM) and 96 h (1 μM) while Saitoh
et al. did not observe any effect of Pioglitazone on the
apoptotic rate of MIN-6 cells exposed to 25 mM glucose
[11] and Ohtani et al. found that troglitazone (10-4 to
10-6 M) induced apoptosis on HIT-15 cell exposed to 7
mM glucose for 72 h [45]. Reasons for the discrepancies
between the studies might be the use of different experi-
mental conditions such as glitazones and glucose
concentrations, different cell lines or islets from different
species, but the controversial results point out the need
for further research on this issue.
It is probable that in vivo the indirect beneficial effects
of TZDs on islets compensate for the potential deleteri-
ous direct effects in the presence of high glucose, given
that previous studies have already demonstrated resto-
ration of islet function in rodents [7,8] and humans
[4-6]. Furthermore, besides hyperglycemia, other con-
ditions not addressed in this study participate in the loss
of β-cell observed in type 2 diabetes, and there are
reports supporting a protective effect of TZDs in pre-
sence of lipotoxicity [44,46,47], deposition of islet amyloid
[48] and endoplasmic reticulum stress [38]. In agreement
with the present study, however, a former in vitro study
has already found that troglitazone protective effects on is-
lets were less pronounced at high glucose [49].
In summary, our data demonstrate for the first time
that the effect of Pioglitazone on pancreatic islet gene
expression profile and apoptosis rate depends on the
glucose concentration, reinforcing the necessity of addi-
tional studies designed to evaluate TZDs effects on the
preservation of β-cell function in situations where
glucotoxicity might be more relevant than lipotoxicity.
Additional files
Additional file 1: Table S1. Primers used in the qRT-PCR assays.
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